Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for LURBINECTEDIN
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
- Lurbinectedin in FET-Fused Tumors
- LINNOVATEL: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
- Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
- Study of Trilaciclib and Lurbinectidin
- Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
- Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
- Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
- Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
- Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
- Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
- Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
- Lurbinectedin + Doxorubicin In Leiomyosarcoma
- A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
- Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
- Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
- Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
- Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
- Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
- Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
- Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
- Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
- Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
- Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
- Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
- A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
- Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
- Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
- Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
- A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
- Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
- Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Clinical trials list
click for details